[GAMUDA] YoY Annual (Unaudited) Result on 31-Jul-2022 [#4]

Stock
[GAMUDA] GAMUDA BHD
Announcement Date
29-Sep-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jul-2022
Quarter
31-Jul-2022 [#4]
Profit Trend
YoY- 37.04%
Quarter Report
Latest QR
Upcoming QR
GAMUDA's Result
GAMUDA's Financial Summary
View:
Show?
Annual (Unaudited) Result
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
Revenue 13,346,712 8,233,552 4,920,829 3,517,218 3,662,964 4,565,062 4,227,060 21.10%
PBT 1,097,381 1,067,575 885,800 786,250 585,462 908,849 729,302 7.04%
Tax -155,070 937,485 -50,140 -154,061 -161,272 -150,654 -164,945 -1.02%
NP 942,311 2,005,060 835,660 632,189 424,190 758,195 564,357 8.91%
-
NP to SH 912,133 1,838,401 806,225 588,316 371,680 706,113 513,883 10.02%
-
Tax Rate 14.13% -87.81% 5.66% 19.59% 27.55% 16.58% 22.62% -
Total Cost 12,404,401 6,228,492 4,085,169 2,885,029 3,238,774 3,806,867 3,662,703 22.52%
-
Net Worth 11,230,466 10,807,049 9,909,248 9,174,381 8,545,994 8,052,542 7,575,172 6.77%
Dividend
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
Div 438,262 1,330,917 306,471 - 150,811 296,412 296,097 6.74%
Div Payout % 48.05% 72.40% 38.01% - 40.58% 41.98% 57.62% -
Equity
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
Net Worth 11,230,466 10,807,049 9,909,248 9,174,381 8,545,994 8,052,542 7,575,172 6.77%
NOSH 2,739,138 2,662,493 2,553,930 2,513,528 2,513,527 2,472,322 2,467,991 1.75%
Ratio Analysis
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
NP Margin 7.06% 24.35% 16.98% 17.97% 11.58% 16.61% 13.35% -
ROE 8.12% 17.01% 8.14% 6.41% 4.35% 8.77% 6.78% -
Per Share
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
RPS 487.26 309.32 192.68 139.93 145.73 184.81 171.31 19.01%
EPS 33.30 69.93 31.96 23.41 14.94 28.60 20.89 8.07%
DPS 16.00 50.00 12.00 0.00 6.00 12.00 12.00 4.90%
NAPS 4.10 4.06 3.88 3.65 3.40 3.26 3.07 4.93%
Adjusted Per Share Value based on latest NOSH - 2,553,930
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
RPS 473.01 291.80 174.39 124.65 129.82 161.79 149.81 21.10%
EPS 32.33 65.15 28.57 20.85 13.17 25.02 18.21 10.03%
DPS 15.53 47.17 10.86 0.00 5.34 10.50 10.49 6.75%
NAPS 3.9801 3.83 3.5118 3.2514 3.0287 2.8538 2.6846 6.77%
Price Multiplier on Financial Quarter End Date
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
Date 31/07/24 31/07/23 29/07/22 30/07/21 30/07/20 31/07/19 31/07/18 -
Price 7.86 4.30 3.75 2.80 3.56 3.71 3.87 -
P/RPS 1.61 1.39 1.95 2.00 2.44 2.01 2.26 -5.49%
P/EPS 23.60 6.23 11.88 11.96 24.07 12.98 18.58 4.06%
EY 4.24 16.06 8.42 8.36 4.15 7.71 5.38 -3.88%
DY 2.04 11.63 3.20 0.00 1.69 3.23 3.10 -6.73%
P/NAPS 1.92 1.06 0.97 0.77 1.05 1.14 1.26 7.26%
Price Multiplier on Announcement Date
31/07/24 31/07/23 31/07/22 31/07/21 31/07/20 31/07/19 31/07/18 CAGR
Date 26/09/24 27/09/23 29/09/22 29/09/21 25/09/20 27/09/19 28/09/18 -
Price 8.01 4.31 3.85 3.02 3.25 3.56 3.36 -
P/RPS 1.64 1.39 2.00 2.16 2.23 1.93 1.96 -2.92%
P/EPS 24.05 6.24 12.20 12.90 21.98 12.45 16.13 6.87%
EY 4.16 16.02 8.20 7.75 4.55 8.03 6.20 -6.42%
DY 2.00 11.60 3.12 0.00 1.85 3.37 3.57 -9.19%
P/NAPS 1.95 1.06 0.99 0.83 0.96 1.09 1.09 10.16%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment